Home - Porton Advanced

Component 18 – 9

End-to-End CRO and CDMO

mRNA, Lentivirus, AAV, Plasmid DNA

Group 18322

10% Discount on
Off-The-Shelf Products!

AAV, mRNA, and Lenti Helper Plasmid

AAV and mRNA

Group 18323

Assisted IND Approvals

IND approvals

8 NMPA, 4 FDA, and 1 Medsafe

6 NMPA, 2 FDA, and 1 Medsafe

Group 18324

CDMO capacity

215,000 sq ft GMP compliant facility

WHO WE ARE

Innately Innovative

At Porton Advanced Solutions, we are committed to accelerating delivery of life-changing advanced therapies to patients. As a C&GT CRO and CDMO company, we provide end-to-end biopharma solutions and services to our clients throughout the development and commercialization of their therapeutics

Our goal is to improve availability and commercial viability of these life-changing treatments by accelerating therapeutic development through our unique, innovative approach.

Porton Advanced Solutions is a subsidiary of the leading CDMO Porton Pharma Solutions. Porton Pharma Solutions is globally recognized and trusted for its process innovation, supply chain performance and compliance with global quality and EHS standards.

Learn More About Us

SERVICES

Cell Engineering

Viral Vectors

mRNA

Plasmid

Lentivirus Helper Plasmids

Expertise tailored to your needs

Our clients include a wide range of biotech and pharmaceutical companies, academic research institutes, and hospitals, each with unique needs spanning across discovery research, drug development, different clinical phases, and commercialization.

Our innovative, integrated approach enables us to respond to the full needs of each individual customer. We provide end-to-end biopharma solutions according to each client’s needs across multiple therapeutic platforms.

Learn More About Our Services

Dedicated, end-to-end support

We have been investing heavily in platform development across the C&GT and Chemistry, Manufacturing, and Control (CMC) spaces.

Our dedicated process and analytical development teams have built up proprietary technologies for client’s licenses and robust platform-based USP/DSP tailored to client’s manufacturing needs.

Our services include gene and cell engineering discovery research and technology licensing, process development and analytical development, testing, drug substances (DS) and drug products (DP), and cGMP manufacturing across plasmids, cell engineering, gene therapy, virotherapy, and mRNA-based therapeutic platforms.